U.S. Markets closed

Environmental Impact Acquisition Corp. (ENVIU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.27-0.08 (-0.77%)
At close: 03:02PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.35
Bid10.27 x 1100
Ask10.38 x 2200
Day's Range10.24 - 10.65
52 Week Range9.77 - 11.84
Avg. Volume2,632
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination

    Environmental Impact Acquisition Corporation (NASDAQ: ENVI) ("ENVI"), a publicly-traded special purpose acquisition company, announced today that ENVI's definitive proxy statement/prospectus (the "Proxy Statement") relating to the previously announced business combination with GreenLight Biosciences, Inc. ("GreenLight"), a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, has been filed with the U.S. Securities and Exchange Commission (

  • American City Business Journals

    RTP biotech primed for expansion on heels of $1.2B SPAC deal

    A biotechnology firm that researches and manufactures ribonucleic acid, or RNA, for use in human and plant health is expanding its footprint in Research Triangle Park ahead of the expected approval of its first product and its entrance onto the public markets. Massachusetts-based GreenLight Biosciences started research and development in RTP for the plant health side of its business near the beginning of the Covid-19 pandemic. About two years later, the company is expanding into a facility that includes 40,000 square feet of lab and office space and 15,000 square feet of greenhouse space.

  • PR Newswire

    GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa

    GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa. IAVI and its partners were among the first to conduct HIV vaccine clinical trials in Africa, and since then, IAVI has sponsored more than 60 vaccine and biologics clinical trials in 13 countries. IAVI has built partnerships with centers of excellence for clinical research in five sub-Saharan African countries, and is developing vaccines and biolog